Regeneron ($REGN), which makes the new wet AMD treatment Eylea, saw its stock falter after a small drugmaker unveiled data from a study testing its AMD treatment in combination with Eylea rival Lucentis. Report
Regeneron ($REGN), which makes the new wet AMD treatment Eylea, saw its stock falter after a small drugmaker unveiled data from a study testing its AMD treatment in combination with Eylea rival Lucentis. Report